AMPHETAMINE SULFATE


Trade Names	AMPHETAMINE SULFATE BENZEDRINE EVEKEO EVEKEO ODT
Synonyms	Amfetamine sulfate Amfetamine sulphate Amphetamine Sulfate Amphetamine sulfate Astedin Benzadrine Benzedrine Dl-amphetamine sulfate Dl-amphetamine sulphate Evekeo Evekeo odt NSC-170999
Status
Molecule Category	Salt-form
UNII	6DPV8NK46S
Parent Compound:	AMPHETAMINE


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	SOFQDLYSFOWTJX-UHFFFAOYSA-N
Smiles	CC(N)Cc1ccccc1.O=S(=O)(O)O
InChI	InChI=1S/C9H13N.H2O4S/c1-8(10)7-9-5-3-2-4-6-9;1-5(2,3)4/h2-6,8H,7,10H2,1H3;(H2,1,2,3,4)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C9H15NO4S
Molecular Weight	233.29
AlogP	1.58
Hydrogen Bond Acceptor	1.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	2.0
Polar Surface Area	26.02
Molecular species	BASE
Aromatic Rings	1.0
Heavy Atoms	10.0

Bioactivity

Mechanism of Action	Action	Reference
Dopamine transporter releasing agent	RELEASING AGENT	KEGG PubMed PubMed


Protein: Norepinephrine transporter Description: Sodium-dependent noradrenaline transporter Organism : Homo sapiens P23975 ENSG00000103546











Protein: Dopamine transporter Description: Sodium-dependent dopamine transporter Organism : Homo sapiens Q01959 ENSG00000142319

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Oxidoreductase	-	-	-	12200	-

Cross References

Resources	Reference
ChEMBL	CHEMBL501
FDA SRS	6DPV8NK46S
PubChem	6055
SureChEMBL	SCHEMBL41203

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).